Abstract

To investigate the molecular basis of β-thalassemia intermedia in Northern Iraq and evaluate its management practices, a total of 74 patients from 51 families were enrolled. The patients were clinically and hematologically reevaluated, and had their β-thalassemia mutations characterized, as well as the number of α-globin genes and Xmn I G γ −158 (C>T) polymorphism studied. Out of 14 β-thalassemia mutations identified, the four most common were IVS-I-6 (T>C) [33.3%], IVS-II-I (G>A) [21.1%], codon 82/83(−G) [10.1%], and codon 8 (−AA) [8.1%]. The most common contributing factors to the less severe phenotype of thalassemia intermedia were found to be the inheritance of mild β-thalassemia alleles and the Xmn I polymorphism, while concomitant α-thalassemia had a limited role. Several complications were documented including: pulmonary hypertension in 20.4%, diabetes mellitus in 1.4%, hypothyroidism in 2.9%, and heart failure in 2.7%, while no documented cases of venous thrombosis were found. Compared to their counterparts in several Mediterranean countries, it appears that our patients were much less frequently transfused and had a lower proportion of patients who were splenectomized, on iron chelation, or hydroxycarbamide therapy. Such practices require further scrutiny to ensure that a better level of care is provided and that growth retardation, skeletal changes, and other complications are prevented or reduced.

Highlights

  • Beta-thalassemia is an inherited autosomal recessive disorder due to reduction or absence of the hemoglobin β-globin chain synthesis, and it presents in one of three clinical phenotypes, namely, thalassemia major, minor, and intermedia

  • Thalassemia intermedia (TI) is a less well-defined clinical entity which encompasses thalassemia patients with a wide spectrum of phenotypes that are more severe than thalassemia minor but milder than thalassemia major [2]

  • All patients diagnosed as thalassemia intermedia at the Duhok thalassemia care center in Northern Iraq were recalled

Read more

Summary

Introduction

Beta-thalassemia (thal) is an inherited autosomal recessive disorder due to reduction or absence of the hemoglobin β-globin chain synthesis, and it presents in one of three clinical phenotypes, namely, thalassemia major, minor, and intermedia. The former is due to homozygosity or compound heterozygosity to β-thalassemia mutations and is usually associated with lifelong dependence on blood transfusion and early presentation. A variety of molecular mechanisms have been implicated, including the inheritance of mild βthalassemia mutations, coinheritance of α-thalassemia, and inheritance of genetic determinants associated with high hemoglobin F production [3] The contributions of these genetic modulators vary in different populations and their determination in these populations is imperative to tailor particular therapeutic strategies

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call